EGFR and lung cancer: Notably, epithelial–mesenchymal transition (EMT) transcription factors such as ZEB1, Slug, and TWIST1 have been identified as drivers of EGFR TKI resistance mediated by EMT, suggesting that these transcription factors could be potential targets for treating EMT-related resistance in lung cancer (121, 147–149).